Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) from Hold to ...

Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.

Sana Biotechnology (SANA) and eBay (EBAY) are two of the stocks rallying this morning despite the market’s losses. Sana is ...

Sana Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -16.99%. The profit margin, also known as the revenue ratio or gross profit ratio ...

Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Sana Biotechnology (SANA – Research Report). The associated price target ...

NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are ...

Analyst Vikram Purohit from Morgan Stanley maintained a Buy rating on Sana Biotechnology (SANA – Research Report) and keeping the price target ...

Sana Biotechnology (SANA) stock soared after Phase 1 data for its cell therapy which, according to Morgan Stanley, has ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...